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ABSTRACT  
Computational techniques are useful to predict interaction models and molecular 
properties for the design of drug delivery systems, such as dendrimers. Dendrimers are 
hyperbranched macromolecules with repetitive building blocks, defined architecture 
and functionality. This work evaluated the impact of surface modifications of 
mannosamine-conjugated multifunctional poly (glutamic acid) (PG)-dendrimers as 
nanocarriers of the tumor associated antigens (TAA) MART-1, gp100:44 and 
gp100:209. Their potential to target antigen presenting cells through molecular 
interactions with mannose receptor (MR1) to promote an efficient and selective 
antitumor immunotherapeutic effect was also evaluated.  
Molecular dynamics (MD) simulations and docking studies were performed. Results 
showed that nitrobenzoxadiazole (NBD)-PG-G4-dendrimer displayed 64 carboxylic 
groups, however the frontier molecular orbital theory study has indicated that only 32 
of those carboxylic groups present on the backbone were available to form covalent 
bonds with either mannosamine or TAA. No differences in the gap energy of HOMO 
of conjugated NBD-PG-G4-dendrimer and LUMO of conjugating agents were 
observed while increasing conjugation loading. When the number of mannosamines 
conjugated to dendrimer was increased from 16 to 32, the conjugated dendrimer 
interacted with the receptor with higher affinity. However, due to absence of available 
carboxylic end groups of backbone chain for further conjugation in a dendrimer with 
32 mannosamine, the 16 mannosamines-NBD-PG-G4-dendrimer was chosen to 
conjugate TAA for added functionality. Docking results showed that the majority of 
TAA-conjugated NBD-PG-G4-dendrimer demonstrated a favorable interaction with 
mannosamine binding site on MR1, thus constituting a promising tool for the targeted 
delivery of TAA.  
Our in silico approach effectively narrows down the selection of the best candidates for 
the synthesis of functionalized PG-dendrimers with desired functionalities. The results 
of this study will significantly reduce the time and efforts required to experimentally 
obtain modified dendrimers for optimal controlled delivery of antigens to targeted DC.  
 
KEYWORDS (5-10 words): peptide dendrimer, poly–glutamic acid, computational 
design, molecular dynamics simulation, receptor docking, tumor associated antigens, 
immunotherapy, cancer  
 
ABBREVIATIONS 
PG - poly (glutamic acid)  
TAA - tumor associated antigens 
MR1 - mannose receptor  
NBD - nitrobenzoxadiazole 
DC - dendritic cells 
MAA - melanoma associated antigens 
APC - antigen presenting cells 
MD - molecular dynamics 
NPT - normal pressure and temperature 
G4 - generation 4 
MHC – Major Histocompatibility Complex 
FMOT - Frontier Molecular Orbital Theory  
HOMO - Highest Occupied Molecular Orbital  
LUMO - Lowest Energy Unoccupied Molecular Orbital 
  
INTRODUCTION 
Cancer is one of the leading causes of death worldwide. Metastatic melanoma is the 
most dangerous type of skin cancer and new treatments are needed due to the 
development of resistance to most of the available radiotherapy and chemotherapy 
regimens currently in use [1, 2]. Cancer cells have the ability to develop distinct tactics 
to evade host immune system, and thus tumor-associated antigens (TAA) recognition 
by T lymphocytes has led to the development of new strategies to strength tumor 
specific immune responses [3]. The TAA recognition, internalization and presentation 
by dendritic cells (DC) to CD8+-T cells and CD4+T-Helper cells specific for tumor 
epitopes can be induced by an effective cancer vaccine [4]. Among the specific 
melanoma associated antigens (MAA), MART-1 (or Melan-A) and gp100:209-217 are 
two highly immunogenic epitopes, presented by major histocompatibility complex 
(MHC) class I, and frequently recognized by tumor-infiltrating lymphocytes (TIL). 
Additionally, gp100:44-59, a MHC class II restricted MAA, has also been used to test 
the effects of MHC class I and class II peptides co-presentation in the induction of 
antigen-specific anti-tumor immune response [5, 6]. Studies have shown that the 
combination of MHC class I and II epitopes derived from the same tumor antigen, 
potentiate anti-tumor effect and long-term tumor-specific immunity [7].    
 Dendrimers are emerging as a new exciting class of potential delivery systems for 
anticancer agents or vaccines for the treatment of solid malignancies [8]. Dendrimers 
are spherical macromolecules with three-domain architecture, consisting of a core, 
branches and terminal end groups. Variation in synthetic methods and starting materials 
can result in a wide range of structures with controlled branching, being as well 
versatile in the nature of terminal groups [9, 10]. The physicochemical features of these 
molecules are unique because of their low viscosity, molecular topology, overall size 
(2 to 10 nm), molecular density and the multiplicity of end groups that can be 
chemically functionalized [9, 11].  
Due to their proper nanoarchitecture, biocompatibility and biodegradability profiles, 
peptide dendrimers are promising drug delivery systems [12]. They are built using 
natural amino acids and can be synthesized either by linear combinations of amino acids 
assembled at a branching point or by using amino acids as focal branching points 
themselves (e.g. glutamic acid, lysine, and aspartic acid) [13]. A particular 
characteristic of peptide dendrimer is its asymmetric arrangement, which create 
different local microenvironments to bind different molecules (drugs, metals or probes) 
[9].  
The functionalization of dendrimers allows the active targeting of antigen presenting 
cells (APC) and consequently the delivery of immune modulator compounds to 
different immune cells. APC, namely DC, have a multiplicity of surface receptors (such 
as MR1) that are involved in the recognition and internalization processes [5].  
An appropriate design of dendrimer conjugates could enable the targeting of a specific 
receptor. Due to its structural complexity, diversity and high degree of chemical space, 
the prediction and rationalization of the 3D structure of dendrimers is difficult. To 
overcome these drawbacks, various degrees of complexity from coarse-grained to full 
atom simulations have been used, namely molecular dynamics (MD) simulations. MD 
allows understanding the interaction process of dendrimers with drugs and 
biomolecules at the atomistic level.  
This work reports a rational approach to design multifunctional poly (glutamic acid) 
(PG)-dendrimers with a high potential to target DC and co-deliver antigens and 
adjuvants simultaneously for a coordinated activation of these APC and consequent 
expansion of T cells. Namely, the conjugation of mannosamine to peptidic dendrimers 
would promote specific interactions with MR1 receptor to enable the targeted delivery 
of one TAA (MART-1, gp100:44–59 (hereafter gp100:44) and gp100:209–217 
(hereafter gp100:209). These multifunctional dendrimers will target relevant cells, but 
are also expected to modulate cancer antigen intracellular trafficking pathway within 
the cytoplasm to enhance the selectivity and effectiveness of antitumor 
immunotherapeutic effect. To monitor the distribution of the dendrimer, 
nitrobenzoxadiazole (NBD) fluorophore was incorporated in its core, forming NBD-
PG-G4-dendrimer that can be further subjected to surface modifications. The main goal 
of this study was to evaluate in silico the effects of NBD-PG-G4-dendrimer surface 
modifications by mannosamine and TAA, on their intermolecular interactions and 
potential for targeted delivery. This computer aided molecular design allowed the 
identification of most suitable candidates for the synthesis of a multifunctional 
dendrimer with optimal targeted delivery of TAA to DC.  
    
METHODS 
Generation of 3D structures of NBD-PG-G4-dendrimer as well as mannosamine and 
three TAA (MART-1, gp100:44 and gp100:209) 
The NBD-PG-G4-dendrimer structures were generated using X-PLOR, as previously 
described by Martinho et al [13]. Mannosamine was built using Maestro software. TAA 
sequences (Table 1) were obtained in [14, 15, 16] and their 3D structures were 
generated by peptide structure prediction using PEP-FOLD web server [17]. All 
structures were saved in *.mae and *.pdb format.  
Table 1: Peptide sequence of tumor-associated antigens (TAA) 
TAA Sequence (aa) 
MART-1 EAAGIGILTV 
gp100:209 - 217 IMDQVPFSV 
gp100:44 - 59 WNRQLYPEWTEAQRLD 
 
Molecular Dynamics simulation of NBD-PG-G4-dendrimer, mannosamine and TAA  
Mannosamine, TAA and NBD-PG-G4-dendrimer structures were imported to Maestro 
2016-2 and then subjected to Protein Preparation Wizard to adjust the protonation states 
of ionizable groups for pH 7 [18].  
Hereafter, all structures were prepared for MD simulations using Desmond. The 
systems were built using the SPC solvation model and the size of the cubic box was 
determined automatically by creating a 10 Å (NBD-PG-G4-dendrimer) or 15 Å 
(mannosamine and TAA) buffer zone around the structures. Appropriate number of 
ions (Na+) was added to neutralize the system with further addition of 150 mM NaCl 
salt.  
The MD simulation, structure minimization and relaxation steps were performed for 10 
ns (mannosamine and NBD-PG-G4-dendrimer) or 20 ns (TAA) at 300K and 1.03 bar 
using NPT. 
 
Determination of electronic properties by semi-empirical methods 
The electronic properties of the dendrimers were determined by semi-empirical 
methods using Mopac 2012 [19]. Input files for Mopac (*.mop) were created using 
Avogadro 2 software [20] and selecting single point energy calculation (for TAA and 
NBD-PG-G4-dendrimer) or geometry optimization (for mannosamine). The keywords 
used were PM7, GRAPHF, MOZYME, NSPA=60, and EPS=78.4. The correct charge 
state of systems was calculated using Vega ZZ 3.0.5.12 and used in conjunction with 
the keyword CHARGE. The position of HOMO and LUMO orbitals of all structures 
were visualized using Jmol 11.2.14 software [21]. Additionally, calculation of 
ionization potential (I = (HOMO−1) – HOMO), electronic affinity (A = HOMO − 
LUMO) and the global reactivity indexes: chemical potential (µ = −1/2 (I + A)), 
electronegativity (χ = −µ), hardness (η =-1/2 (I − A)), softness (S = 1/η) and 
electrophilicity (ω = χ 2/ 2η).  
Docking of mannosamine and TAA to NBD-PG-G4-dendrimer  
Docking studies of mannosamine and TAA to NBD-PG-G4-dendrimer to MR1, were 
performed using HEX 8.0.0 software [22]. The 3D structures of MR1 were obtained in 
RCSB Protein Data Bank [23], and by homology modelling using Swiss-Model online 
webserver. The total energy of interactions was calculated based on shape and 
electrostatics as correlation types followed by OPLS post processing minimization. 
Saved files of 20 docking poses were visualized in Maestro 2016-2. 
 
Conjugation of mannosamine and TAA to NBD-PG-G4-dendrimer and respective 
analysis 
Mannosamine and TAA amino groups where the LUMO were located were conjugated 
to carboxylic groups of NBD-PG-G4-dendrimers where HOMO was located, using 
Maestro 2016-2 software. Firstly, 1, 16 and 32 mannosamines or 1, 5 and 10 TAA, 
individually, were conjugated to NBD-PG-G4-dendrimer. Secondly, 16 mannosamines 
were conjugated to NBD-PG-G4-dendrimer structure, which was further used to 
conjugate 2 or 4 TAA.  
For all conjugated structures, MD simulations were performed using fully solvated 
systems that were built using SPC solvation model, 10 Å as the size of the cubic box 
around the conjugated structures with addition of ions (Na+) and 150 mM NaCl salt. 
The MD simulations that followed initial structure minimization and relaxation steps 
were performed for 1ns at 300K and 1.03 bar. 
The determination of electronic properties and the docking studies of the mannosamine 
or TAA NBD-PG-G4-dendrimer conjugates and TAA 16 Mannosamine-NBD-PG-G4-
dendrimer were performed as described above.  
 
RESULTS and DISCUSSION 
Computational modeling and MD are valuable tools for the design and optimization of 
drug candidates and polymeric structures. Thus, there is a growing interest in applying 
computational chemistry tools to study dendrimers. Molecular modeling of dendrimers 
offers a means to study conformation and different features of the dynamic behavior of 
dendrimers, on the atomistic level, that are difficult to probe experimentally. Thereafter, 
these approaches allow the elucidation of some of the key interactions of functionalized 
dendrimers with therapeutic molecules and biological systems, such as proteins and 
receptors as well as with lipid membranes.  
As a result, our in silico strategy was employed to understand the impact of the surface 
modification of dendrimers, with distinct numbers of TAA and mannosamine 
molecules, on their conformation and dynamic interactions with target receptors.  
 
Generation of 3D structures: NBD-PG-G4-dendrimer, mannosamine and TAA (MART-
1, gp100:44 and gp100:209) 
The three-dimensional structures of NBD-PG-G4-dendrimer, as well as mannosamine 
and three different TAA (MART-1, gp100:44 and gp100:209) were generated. The 
generation 4 (G4) of PG dendrimer has 64 carboxylic end groups (32 on the backbone 
chain and 32 on the side chains) available for covalent interaction with mannosamine 
and/or TAA. Additionally, incorporation of NBD (a fluorophore) in the core, aimed to 
follow the dendrimer delivery in the biological studies, was optimal at PG G4 
dendrimer. Under these conditions, NBD would not be exposed to the surface thus 
resulting in NBD-PG-G4-dendrimers as the core for further surface modifications. We 
predicted that the fluorophore was fully incorporated in the core of the dendrimer, thus 
not forming undesired intermolecular interactions with other molecules or targets [13]. 
The predicted structures of TAA on their own, resembled some of their structural 
features in experimentally-determined complexes with MHC class I biopolymers, i.e. 
MART-1 complexed with HLA-A2 found in the Protein Data Bank entry 3MRO. 
Therefore, these predicted structures were further used in the conjugation studies. 
The resulting structures were submitted to MD simulations, using the conditions 
previously described in Methods. In each trajectory of MD simulation, 1000 different 
structures were saved and clustered to select the best representative structures for the 
conjugation studies. Moreover, analysis of all trajectory profile allowed the study of 
conformational dynamic structures of NBD-PG-G4-dendrimer, as well as of all TAA, 
individually.  
Calculation of electronic properties of NBD-PG-G4-dendrimer, mannosamine and 
TAA (MART-1, gp100:44 and gp100:209), individually and conjugated 
The Frontier Molecular Orbital Theory (FMOT) hypothesize that the interaction 
between the HOMO and the LUMO orbitals of molecules undergoing a reaction, can 
provide a good approximation of reaction outcome [24].  The reaction occurs with 
increasing and possible overlap of HOMO and LUMO orbitals. Results demonstrated 
that HOMO molecular orbitals of the dendrimer were located on the carboxylic acid 
groups from backbone chain and it could preferentially interact with LUMO molecular 
orbitals of amine group from mannosamine or TAA, as shown in Figure 1A. These 
results are in agreement with a previous study performed by our group, where HOMO 
of a generation 3.5 PAMAM is located on one of the terminal carboxylic acid groups 
[25]. Moreover, HOMO and HOMO-1 orbitals are located at the end groups of the 
branches of the dendrimer, being this position favorable for further conjugations. The 
calculations of HOMO and LUMO orbital energies enabled the prediction of the next 
conjugation sites on dendrimer for additional molecules, such as mannosamine and 
TAA (Figure 1B and C, respectively). We chose the most representative conformation 
per analogue for the calculation of the electronic properties, having in consideration the 
time required for these electronic calculations, the demand for computational resources 
and the information that most probably will be obtained. 
The conjugation of NBD-PG-G4-dendrimer with different molar ratios of 
mannosamine and each TAA was performed. NBD-PG-G4-dendrimer was conjugated 
with 1, 16 and 32 mannosamines, and separately with 1, 5 and 10 individual TAA. The 
addition of the first mannosamine or TAA is favorable because the HOMO is located 
on the surface carboxylic group and exposed for reaction (Figure 1D). 
 Figure 1 – Representative HOMO and LUMO orbitals of NBD-PG-G4-dendrimer 
(green) (A), mannosamine (purple) (B), MART-1 (purple) (C) and mannosamine-
conjugated to NBD-PG-G4-dendrimer (green) (D). In D, the HOMO and LUMO 
orbitals of mannosamine conjugated to NBD-PG-G4-dendrimer are placed in the 
opposite side of the first mannosamine connected to dendrimer (black circle). 
Then, the difference in energies between HOMO of dendrimer and LUMO of 
mannosamine / TAA for subsequent additions was determined and analyzed. The 
obtained results showed no significant differences in the gap energy of HOMO/LUMO 
for all NBD-PG-G4 dendrimer conjugates, despite the increase in size and number of 
occupied carboxylic groups (Table 2). These results could suggest a similar reactivity 
of the dendrimer for the conjugation of mannosamine and TAA regardless of number 
of modified terminal carboxylic groups.  
Table 2 also shows the values of the calculated global chemical reactivity parameters 
for the conjugation of NBD-PG-G4-dendrimer to 1, 16 and 32 mannosamines, and 
separately to 1, 5 and 10 individual TAA. The ionization potential values increased 
with the augment of mannosamine molecules linked to NBD-PG-G4-dendrimer, while 
for the conjugation of TAA, the values maintained unchanged. The electronic affinity 
values were lower in NBD-PG-G4-dendrimers conjugated with higher number of 
mannosamines (from 1 to 32). Again, these values remained unchanged despite the 
number of TAA conjugated to the NBD-PG-G4-dendrimer. No differences were 
observed in the values of global reactivity indexes (chemical potential, 
electronegativity, hardness, softness and electrophilicity) obtained for the conjugation 
of NBD-PG-G4-dendrimer to 1 and 16 mannosamines, and separately to 1, 5 and 10 
individual TAA. However, there was a notable change in value of hardness from -3.03 
to -3.55 for the NBD-PG-G4-dendrimer conjugated with 32 mannosamines.   
FMOT also hypothesized that smaller gaps among HOMO and LUMO may lead to 
higher probability for the reaction [24]. Having in consideration the size of 
mannosamine, the results suggest that this molecule could occupy all 64 binding sites 
of the NBD-PG-G4-dendrimer. The similar trend would be expected for TAA, 
however, due to the size of the peptides, the complete conjugation is unlikely to occur 
due to steric hindrance by those already conjugated peptides.  However, our results 
demonstrated that the amine group of mannosamine and each TAA bound preferentially 
to the carboxylic group of the backbone chain, instead of the carboxylic group on side 
chains. Therefore, only 32 terminal groups can be expected to act as acceptors for 
conjugations by mannosamine, as there is a notable change in hardness, thus indicating 
that further conjugation with mannosamine may be precluded.   
Table 2 – Values of the highest occupied molecular orbital (HOMO) energy determined for NBD-PG-G4-dendrimer (and its conjugated form) and 
the lowest unoccupied molecular orbital (LUMO) of mannosamine (0.68 eV). MART-1 (0.16 eV). gp100:209 (-0.25 eV) or gp100:44 (-0.34 eV), 
according with used in conjugated structure. Additionally, vibrational analyses were performed, namely ionization potential and the electronic 
affinity calculations. The global reactivity indexes specifically chemical potential, electronegativity, hardness, softness and electrophilicity 
calculations were also carried out. 
Structure 
HOMO 
(eV) 
HOMO 
- 1 (eV) 
LUMO 
(eV) 
HOMO -
LUMO* 
gap (eV) 
Ionization 
potential (I) 
Electronic 
affinity (A) 
Chemical 
potential (µ) 
Electronegativity 
(χ) 
Hardness 
(η) 
Softness 
(S) 
Electrophilicity 
 (ω) 
Mannosamine -10.70 -11.29 0.68 - -0.59 -11.38 5.98 -5.98 -5,40 -0,19 -3,32 
MART-1 -9.52 -9.95 0.16 - -0.43 -9.68 5.05 -5.05 -4,63 -0,22 -2,76 
gp100:209 -8.90 -9.48 -0.25 - -0.58 -8.65 4.61 -4.61 -4,04 -0,25 -2,64 
gp100:44 -8.48 -8.60 -0.34 - -0.12 -8.14 4.13 -4.13 -4,01 -0,25 -2,13 
NBD-PG-G4-dendrimer : mannosamine -7.99 -8.47 -2.04 8.77 -0.48 -5.95 2.88 -2.88 -2,74 -0,37 -1,89 
NBD-PG-G4-dendrimer : mannosamine (1:1) -7.50 -7.79 -2.06 8.18 -0,29 -5.44 3.34 -3.34 -2,58 -0,39 -1,59 
NBD-PG-G4-dendrimer : mannosamine (1:16) -8.58 -8.74 -2.36 9.26 -0,16 -6.22 3.32 -3.32 -3,03 -0,33 -1,68 
NBD-PG-G4-dendrimer : mannosamine (1:32) -8.96 -8.99 -1.83 9.64 -0,03 -7.13 3.14 -3.14 -3,55 -0,28 -1,81 
NBD-PG-G4-dendrimer : MART-1 (1:1) -8.06 -8.12 -2.13 8.22 -0,06 -5.93 2.97 -2.97 -2,94 -0,34 -1,53 
NBD-PG-G4-dendrimer : MART-1 (1:5) -8.15 -8.08 -2.27 8.31 0,07 -5.88 2.90 -2.90 -2,98 -0,34 -1,42 
NBD-PG-G4-dendrimer : MART-1 (1:10) -8.79 -8.80 -1.96 8.95 -0,01 -6.83 3.42 -3.42 -3,41 -0,29 -1,72 
NBD-PG-G4-dendrimer : gp100:209 (1:1) -7.98 -8.19 -2.09 7.73 -0,21 -5.89 3.05 -3.05 -2,84 -0,35 -1,64 
NBD-PG-G4-dendrimer : gp100:209 (1:5) -8.04 -8.16 -2.35 7.79 -0,12 -5.69 2.90 -2.90 -2,79 -0,36 -1,52 
NBD-PG-G4-dendrimer : gp100:209 (1:10) -7.80 -7.94 -2.35 7.55 -0,14 -5.45 2.80 -2.80 -2,66 -0,38 -1,47 
NBD-PG-G4-dendrimer : gp100:44 (1:1) -7.87 -7.88 -2.32 7.53 -0,01 -5.55 2.78 -2.78 -2,77 -0,36 -1,40 
NBD-PG-G4-dendrimer : gp100:44 (1:5) -7.91 -7.95 -2.46 7.57 -0,04 -5.45 2.74 -2.74 -2,71 -0,37 -1,39 
NBD-PG-G4-dendrimer : gp100:44 (1:10) -7.77 -7.85 -2.53 7.43 -0,08 -5.24 2.66 -2.66 -2,58 -0,39 -1,37 
Docking studies – mannose receptor (MR1) and mannosamine or TAA conjugated to 
NBD-PG-G4-dendrimer 
Docking studies should predict the best orientation of a structure to another structure, 
or corresponding receptor, to form a more stable complex. MR1 has an extracellular 
portion constituted by various C-type carbohydrate recognition domains that allow 
recognition of a diverse range of glycoconjugate ligands [26]. As result, MR1, which 
is present in macrophages and DC, plays a central role in the coordination of innate and 
adaptive immune responses through the increase of uptake and consequent processing 
of soluble glycoconjugates released from pathogens [23].   
 Mannosamine is the principal ligand that binds to MR1 receptor. The augment on 
mannosamine in the dendrimeric structure could potentiate the interaction with MR1 
receptor and facilitate intracellular trafficking and processing.  The structure of MR1 
(1EGI) was obtained in Protein Data Bank. However, due to the poor definition of the 
active site responsible for the mannosamine binding and consequently obtained poor 
docking results, a new 3D structure of MR1 was generated by homology modelling. 
This resulted in a model generated by Swiss-Model server in automated mode based on 
the 1EGI structure, as a template. All docking studies were performed using the model 
2 that had well defined mannosamine binding site in a good agreement with previously 
identified residues [23] and hereafter referred only as MR1.   
Obtained results from docking analysis showed that mannosamine (Figure 2A) alone 
interacted with the residues that define receptor MR1 binding site, constituted by amino 
acids glutamic acid (position 743) and asparagine (positions 745 and 746), as 
previously observed by Feinberg et al [23]. The TAA had preferential interactions with 
other surfaces on the MR1, without any selectivity. Furthermore, all tested 
mannosamine and TAA conjugated to NBD-PG-G4-dendrimer bound to the MR1 
receptor, showing similar profiles. Notably, increasing the number of mannosamine 
conjugated to NBD-PG-G4-dendrimer (from 16 to 32 mannosamines), the conjugates 
formed more favorable interactions with mannosamine binding site, as showed in 
Figures 2B and 2C, respectively. This effect could be justified by the balanced charge 
of total dendrimer and changed conformations with higher loadings of mannosamine.  
Although 32 mannosamine-linked NBD-PG-G4-dendrimer had better docking profile 
compared with 16 mannosamine-linked NBD-PG-G4-dendrimer, it was found that the 
LUMO of dendrimer conjugated with 32 mannosamines was not located on the 
carboxylic group at the glutamic acid side chain, and therefore, according to FMOT, 
further conjugation of TAA is not likely to occur. Due to these constrains in 32 
mannosamine-linked NBD-PG-G4-dendrimer, the 16 mannosamine-linked NBD-PG-
G4-dendrimer structure was selected as a candidate for further conjugation with two 
and four TAA.  
 
Figure 2 – Docking conformations of mannosamine (green, red and blue structure) (A), 
16 mannosamine conjugated to NBD-PG-G4-dendrimer (grey, green, red and blue 
structure) (B) and 32 mannosamine conjugated to NBD-PG-G4-dendrimer (grey, green, 
red and blue structure) (C) to the core of mannose receptor, MR1, represented by three 
amino acids: Glutamic acid (position 743), aspartame (position 745 and 746) (grey, 
blue and red). D, E and F show the electrostatic surface representations of 
mannosamine, and 16 and 32 mannosamines conjugated to NBD-PG-G4-dendrimer, 
respectively. In A, mannosamine is directly docked in the core of MR1. In B, 16 
mannosamine conjugated to NBD-PG-G4-dendrimer are not so close to the receptor 
core when compared with 32 mannosamine conjugated to NBD-PG-G4-dendrimer (C). 
 
Conjugation of TAA to 16 mannosamine-linked NBD-PG-G4-dendrimer and respective 
analysis (molecular dynamics simulation and docking) 
The combination of different TAA with mannosamine-linked NBD-PG-G4-dendrimer 
could potentiate the targeted immune response. Due to possible steric constrains that 
could arise from the conjugation of high number of TAA, the conjugation of only two 
and four TAA to 16 mannosamine-linked NBD-PG-G4-dendrimer was explored.  
The conjugation of the first TAA (MART-1, gp100:44 and gp100:209) was performed 
according to the obtained HOMO from 16 mannosamine-linked NBD-PG-G4-
dendrimer. The conjugation sites are localized on the carboxylic acid groups from 
backbone chain of 16 mannosamine-linked NBD-PG-G4-dendrimer, similarly to the 
previously described conjugation sites for NBD-PG-G4-dendrimer.  
MD simulations were performed during 1 and 10 ns for 4 TAA connected to 16 
mannosamine-linked NBD-PG-G4-dendrimer, however no major differences were 
observed.  HOMO for higher number conjugations (2, 3 and 4 TAA) were localized on 
the carboxylic groups close to first conjugations site, thus leaving mannosamine rich 
surface available to interact with MR1 and promote the targeted delivery of the 
multifunctional dendrimer (Figure 3).  
 
Figure 3: Representative HOMO and LUMO orbitals of two MART-1 linked to 16 
mannosamine – NBD-PG-G4-dendrimer (green). The HOMO and LUMO orbitals of 
TAA- 16 mannosamine conjugated to dendrimer are placed in COOH groups of the 
closer branches to TAA instead of opposite side of MART-1 position. Arrows show the 
MART-1 positions. 
 
Docking studies of multifunctional dendrimers with increasing number of TAA 
conjugated to 16 mannosamine-linked NBD-PG-G4-dendrimer resulted in higher 
likelihood of sugar moiety on the dendrimer surface to interact with mannosamine 
binding site on the MR1 receptor. Thus, 4 TAA associated to 16 mannosamine-linked 
NBD-PG-G4-dendrimer were the conjugates that presented a better docking profile. 
Among these results, MART-1 associated to 16 mannosamine-linked NBD-PG-G4-
dendrimer did not show a favorable interaction with the binding site on the MR1 (Figure 
4A), compared with 4 gp100:44 or gp100:209 associated to 16 mannosamine-linked 
NBD-PG-G4-dendrimer (Figure 4 B). Therefore, MART-1 is not a good TAA to be 
conjugated with 16 mannosamine-linked NBD-PG-G4-dendrimer, which most likely 
result from the preferential non-specific interactions with MR1 that would not warrant 
the targeted delivery utilizing mannosamine on the dendrimer surface.  
 
Figure 4: Docking conformations of TAA (blue) linked to 16 mannosamine-
conjugated NBD-PG-G4-dendrimer (grey, green and red structure) and bound to the 
core of mannose receptor, MR1, represented by three amino acids: glutamic acid 
(position 743), aspartame (position 745 and 746) (grey, blue and red). In A) MART-1 
linked to 16 mannosamine conjugated to NBD-PG-G4-dendrimer is further away from 
the core of MR1, compared with gp100:209 (B) or gp100:44 (not shown) linked to 16 
mannosamine-conjugated NBD-PG-G4-dendrimer that are closer to the amino acids of 
the core of MR1.  
Therefore, these in silico studies suggest that most likely candidates that would have 
viable synthetic route and favorable interaction profile with MR1 to achieve targeted 
delivery of TAA to DC are: gp100:44 or gp100:209 conjugated to 16 mannosamine-
linked NBD-PG-G4-dendrimers.  
 
CONCLUSIONS 
Understanding molecular interactions is fundamental to improve targeted delivery 
systems. The MD, docking studies and calculation of electronic properties performed 
for mannosamine, TAA and all conjugated forms provided an in silico tool for the 
design of multifunctional dendrimers and assessment of their potential for targeted 
delivery. Particularly, docking studies can offer greater insight on the interaction of 
dendrimers with bioactive molecules and biological targets. The optimal design of a 
dendrimer with a modified core and functionalized surface allows monitoring their 
cellular uptake without affecting the desired biological activity. Additionally, a targeted 
delivery of TAA will increase their uptake and processing, favoring an extensive 
presentation of the epitope to T cells. 
This approach suggested candidates for full mechanistic studies on a reduced set of 
molecules with optimized properties. Important results were obtained, namely showing 
that mannosamine had no steric impediment to connect to 64 carboxylic groups on the 
surface of NBD-PG-G4-dendrimer. Additionally, electronic studies from MD 
simulation showed that the carboxylic acid groups on the backbone chain are the 
preferred site for chemical conjugation when compared to the carboxylic group of the 
side chain, thus suggesting a reduced likelihood to achieve full conjugation of all 64 
terminal carboxylic groups. It was also verified by electronic studies that reactivities of 
mannosamine and TAA to connect to dendrimeric structures are similar. However due 
to the steric hindrance, TAA may not have the same conjugation efficiency, which 
would prevent their successful conjugation to all surface carboxylic groups.  
Differences in docking of dendrimer structures to MR1 receptor were observed. Despite 
that the 32 mannosamines conjugated to NBD-PG-G4-dendrimer showed the best 
interaction profile with MR1, lack of availability of the carboxylic acid groups on the 
backbone chain suggested that this is not a good candidate for further conjugation of 
TAA.  
Therefore, the NBD-PG-G4-dendrimer conjugated with 16 mannosamines was chosen 
as a platform to further bind TAA. It was observed that after conjugating first TAA on 
the 16 mannosamine NBD-PG-G4-dendrimer, the conjugation sites for subsequent 
TAA conjugation were situated in a close proximity. This creates the opportunity to 
have TAA rich surfaces on one side of the dendrimer, while leaving the mannosamines 
on the opposite side free for favorable interactions with MR1.     
This thorough study thus allowed the selection of the best candidates for future 
experimental work focused on the development of a cancer vaccine, through the 
synthesis of a lower number of PG G4 dendrimer conjugates to achieve an optimal 
system for targeted delivery of TAA.   
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